25,071,235Cost of sales
22,833,23111,316,26139,415,14320,967,733Operating expenses:Research and development expenses
1,799,803924,4683,189,8462,171,222Selling, general and administrative expenses
21,193,23210,868,37237,044,78519,237,384Amortization of intangible assets
231,959267,638463,290530,234Operating income (loss)
(391,763)(744,217)(1,282,778)(971,107)Other income (expense), netAmortization of debt discount
———(1,328,439)Interest expense, net
(8,429)(13,172)(29,453)(27,976)Income (loss) before income tax provision
SOURCE MiMedx Group, Inc.
Copyright©2014 PR Newswire.
All rights reserved
Related medicine technology :
1. MiMedx Files Its Initial Investigational New Drug Application
2. MiMedx Announces Next Steps After Discussions With The FDA
3. Seven Poster Abstracts Highlight MiMedx Allografts at the 10th Annual Desert Foot Conference
4. MiMedx to meet with FDA in Mid-October
5. MiMedx Announces Conference Call To Discuss FDA "Untitled Letter" And Reiterate Guidance
6. MiMedx Addresses FDA Untitled Letter And Reiterates 2013 And 2014 Guidance
7. MiMedx Group, Inc. Announces Release Date for 2013 Second Quarter Results
8. MiMedx Announces 2012 Results
9. MiMedx Group to Present at the 6th Annual OneMedForum
10. MiMedx Group to Present at the Stifel Nicolaus 2012 Healthcare Conference
11. Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc.